This argues strongly for the inclusion of NR5A1 in 1st-tier genetic testing panels for any child presenting with unexplained hypospadias, ambiguous genitalia, or gonadal dysgenesis, especially when accompanied by biochemical evidence of hypergonadotropic hypogonadism. Here, NR5A1 is linked to gonadal dysgenesis.